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Abstract
NANOMEDECINE DRUG DELIVERY ACROSS MUCOUS MEMBRANES
By Michael G. Lancina III
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.
Virginia Commonwealth Univeristy, 2017.
Major Director: Dr. Hu Yang, Associate Professor, Chemical and Life Science Engineering
Control over the distribution of therapeutic compounds is a complex and somewhat overlooked
field of pharmaceutical research. When swallowing a pill or receiving an injection, it is commonly
assumed that drug will spread throughout the body in a more or less uniform concentration and
find its way to wherever it is needed. In truth, drug biodistribuition is highly non-uniform and
dependent on a large number of factors. The development of advanced drug delivery systems to
control biodistribution can produce significant advances in clinical treatments without the need to
discover new therapeutic compounds. This work focuses on a number of nanostructured materials
designed to improve drug delivery by direct and efficient transfer of drugs across one of the body’s
external mucous membranes.
Chapter 1 outlines the central concept that unites these studies: nanomaterials and cationic particles
can be used to delivery therapeutic compounds across mucous membranes. Special attention is
given to dendritic nanoparticles. In chapter 2, uses for dendrimers in ocular drug delivery are
presented. The studies are divided into two main groups: topical and injectable formulations.
xv

Chapter 3 does not involve dendrimers but instead another cationic particle used in transmembrane
drug delivery, chitosan. Next, a dendrimer based nanofiber mat was used to deliver anti-glaucoma
drugs in chapter 4. A three week in vivo efficacy trial showed dendrimer nanofiber mats
outperformed traditional eye drops in terms of intra-ocular pressure decrease in a normotensive rat
model. Finally, we have developed a new dendrimer based anti-glaucoma drug in chapter 5.
Collectively, these studies demonstrate some of the potential applications for nanotechnology to
improve transmembrane drug delivery. These particles and fibers are able to readily adhere and
penetrate across epithelial cell lays. Utilizing these materials to improve drug absorption through
these portals has the potential to improve the clinical treatment of wide variety of diseases.

xvi

Chapter 1
Background and Significance
1.1 Transmembrane Drug Delivery
Direct drug delivery across one of the body’s mucous membranes is a very attractive route of
administration for several reasons. Passing therapeutics directly though these barriers can improve
both tissue specificity and access depending on the application, and it is considered less invasive
than injections.7 Mucous membranes are found at the external surfaces of the eyes, mouth,
reproductive organs, respiratory system, and gastrointestinal tract. The specific properties of these
membranes vary considerably, but they share the same basic structure. (Figure 1.1) All of these
membranes are characterized by an epithelial cell layer coated in a viscous, constantly regenerating
fluid known as mucous. The mucous serves as a lubricant, but it also is a critical selective barrier
against external pathogens and particulates.8 Since the underlying cell layer is designed for
selective solute transport, it has a much higher permeability than dermal epithelia, but this is highly
dependent on the compound being absorbed.9 This is because there are multiple processes by
which drugs can cross the epithelial cell layer including transcellular and paracellular routes.
Transcellular permeation, either by active transport or simple diffusion is rapid but highly
selective, so it is not feasible for most compounds. Paracellular permeation though the gaps in
epithelial cells is slower, unless the membrane is modified in some way to loosen these junctions.10
Inflammation naturally disrupts cell junctions, making it one way to direct site-specific absorption
of drugs or drug vehicles.11 Certain compounds such as detergents or chitosan are also known to
temporarily disrupt cell-cell gap junctions and increase the permeability of the membrane.12
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Figure 1.1: Typical mucosa structure. This schematic depicts the buccal mucosa, which lines
the oral cavity, but in general all mucous membranes contain a mucous covered epithelium
anchored to a basal lamina. For drugs to reach systemic circulation, they must penetrate to the
vascularized lamina propia. Adapted from Harris et al.1
Direct membrane absorption also avoids processes that can degrade or remove certain drugs, the
low pH of the upper GI tract and first pass filtration though the portal system, respectively. This
makes it an ideal delivery system for unstable therapeutics such as peptide drugs and genes. Noninvasive delivery of bioactive insulin has long been a target of transmembrane drug delivery, with
oral and pulmonary systems showing the most promise.13,14 In some cases, transmembrane drug
delivery can also dramatically improve target specificity. Blood perfusion is highly non-uniform,
so simple systemic drug delivery results in an equally non-uniform drug distribution. For organs
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such as the eye, this produces low concentrations at the desired site while concentrations in high
perfusion organs such as the liver can reach dangerous levels.15
There are downsides to transmembrane drug delivery as well. The structure of both the mucous
and epithelial layers are highly complex and much about their physiology remains understudied.16
Drug absorption rates can vary widely depending on individual differences and diseases states.
The immune function of mucous membranes is a relatively new field of study, and there is concern
that use of permeation enhancers can expose patients to risk of pathogen invasion.17 Even with
these problems, cutting edge modeling and experimental studies are revolutionizing our
understanding of drug kinetics at the mucosal interface.18 As these techniques become more
sophisticated, the potential for transmembrane drug delivery will increase as well.
1.1.1 Ocular Drug Delivery: Transcorneal drug delivery is a unique case deserving of special
consideration for a few reasons. Most importantly, it is perhaps the organ where advanced
transmembrane drug delivery systems have the most potential for clinical impact.19,20 Existing
strategies for ocular drug delivery are particularly deficient in terms of both efficiency, reliability,
and safety. As mentioned above, the eye receives low blood perfusion overall in terms of volume,
but in addition it is isolated by an extra selective membrane similar to the blood brain barrier. The
delicate nature of the organ also makes injections problematic.21 All of these procedures must be
performed by health care professionals, and still there can be serious complications. The pool of
ocular disease patients is also massive. Glaucoma alone threatens the sight of over 60 million
people worldwide, most of which administer highly inefficient eye drops several times per day.22
Simple saline eye drops are largely ineffective because of the structure of the corneal epithelium
and ocular mucosa. (Figure 1.2) The cornea is covered in a simple epithelium (there is only one
cell type, unlike the stratified epithelium of the gut) where the cells are completely surrounded by
3

tight junctions.23 In contrast with other mucous membranes, the ocular epithelium is very delicate.
Corneal wounds heal slowly, so any permeation enhancers used must meet a higher standard of
cytocompatablity than in other tissues.24 Ocular mucous serves a similar function as other mucous
layers, but it contains additional muscins to more aggressively clear particulates and pathogens
which constantly barrage the eye surface.25 This is the reason for the relatively rapid turnover of
tear fluid. These two physiologic phenomenon combine to greatly limit drug permeation for almost
all topically applied ocular drugs, but novel vehicle strategies are working to overcome this.

4

Figure 1.2: Barriers to ocular drug delivery. The structure of the corneal epithelium is unique.
The aqueous layer above the mucin layer is relatively thick, and turnover is rapid. The cornea itself
is a covered by a narrow but tightly bound epithelial cell layer. Adapted from Janagam et al.2
1.2 Nanoparticles
Nanoparticles have been a fundamental aspect of pharmaceutical engineering since medicine has
existed, but only with the development of technologies to image and characterize sub-micron
particles has their development become a deliberate science.26 Much of this work is focused on
using nanoparticles as drug delivery vehicles. Several classes of these nanocarriers exist including
solid nanoparticles, liposomes, micelles, linear polymers, and dendrimers. (Figure 1.3) All of
these nanocarriers can deigned to solubilize drugs at higher concentrations, control drug
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distribution, and co-deliver imaging agents, depending on particle properties such as size, charge,
and surface functionalization.27

Figure 1.3: Drug nanocarriers. There are several different classes of polymer based nanocarriers.
Drugs can be covalently or ionically coupled, or encapsulated in the core of the particle. Typical
size ranges for these carriers vary widely. Adapted from Kamaleddin et al.3
Particle size and charge have the largest influence over carrier distribution. In terms of size
nanocarriers can be divided into three basic categories, small particles less than 100nm, medium
particles between 100 and 200nm, and large particles over 200nm. In general small particles are
able to diffuse away from their site of application faster.28 100nm is used as a critical cutoff because
carriers under this size can pass though the capillary endothelium, meaning they can enter and exit
circulation and possibly be used for targeted delivery vehicles. Medium sized particles are not able
to readily cross normal endothelium, but can pass through the larger pores that open up during
inflammation. This means they can be used as passively targeted vehicles, as they will only exit
circulation in areas of active inflammation or tumor growth. Large particles over 200 nm are
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recognized by the immune system and aggressively removed by phagocytotic cells, so they have
a short circulation time.29 Still they can be useful in some applications depending on the target.
Surface charge is also a critical parameter to consider when trying to design nanocarriers.
Changing the net charge of a particle while holding other properties constant will have a dramatic
effect on how the carrier interacts with biologic membranes and extracellular matrix proteins. Cell
membranes carry a net negative charge, so positively charged nanoparticles will more readily
penetrate into cells and across selective membranes.30 However, these strongly charged particles
also tend to be toxic, and can be subject to renal clearance. Passivating polymers like
poly(ethylene) glycol (PEG) neutralize the charge and increase the circulation time and
biocompatibility of these particles so they can be used safely in vivo.31 Anionic particles avoid
strong interaction with most extracellular components, but the presence of the negative charge
enables them to form complexes with cationic drugs or other compounds.
Surface functionalization with direct cell binding ligands is a way to produce even more targeted
nanocarrier distributions. There is an incredibly variety in the types of cell binding groups now
used for these approaches. They can be highly specific targets such as monoclonal antibodies,
selectively metabolized compounds such as folate, or entirely synthetic systems like aptamers.
Clinical use of these vehicles is complicated by factors such as target specificity, carrier stability,
and the immune system, but these vehicles have the potential to revolutionize the delivery of things
like chemotherapeutics or siRNA in the near future.
1.2.1 Dendrimers: Dendrimers are a unique class of polymeric nanoparticles characterized by a
highly organized branching structure. Synthesis of dendrimers involves sequential attachment of
alternating branching units, resulting in a linear increase in the size of the particles but an
exponential increase in their molecular weight and surface groups. (Figure 1.4) In contrast with
7

linear polymers this synthesis results in a much more dense structure, with a very high number of
available terminal groups relative to the particle size. This makes dendrimers extremely flexible
nanocarriers, able to simultaneously delivery drugs, imaging agents, targeting moieties, and even
nucleic acids through both covalent attachments and ionic complexing. They also deliver these
therapeutics at comparatively high payloads while maintaining a small enough size to utilize
multiple cell entry or bypass pathways depending on the surface modifications or generations used.

Figure 1.4: Dendrimers as Flexible Delivery Vehicles. The organized branching structure of
dendrimers makes many surface groups available for functionalization. The allows dendrimers to
serve as drug delivery vehicles combining direct cell targeting, imaging probes, and gene delivery
into a single compact vehicle.
There is a large and growing number of dendritic polymers, but poly(amidoamine) (PAMAM)
dendrimers are the most well studied and commercialized family. For successful trans-membrane
delivery, the most beneficial properties of these materials are their variable surface charge and
dense structure. The small size and cationic character of full generation (amine terminated)
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PAMAM dendrimers allow them to bind to extracellular mucins and penetrate through the
epithelial cell layer through both transcellular and paracellular routes.
1.3 Electrospun Nanofibers
Electrospinning is simple and versatile technique for fabricating sub-micron fibers. The process is
analogous to mechanical fiber pulling techniques, but a DC electric field is used pull polymers in
solution towards a grounded collecting surface. If conditions are right, the polymer solution is
drawn into a narrow but continuous stream. The solvent dries as the stream travels through the air
and a dry fiber of entangled polymer molecules is deposited. Changing electrospinning parameters
such as the strength of the electric field, air gap distance, and solution concentration can be used
to modulate properties of the fibers such as size, density and alignment. The same process can also
be used to fabricate electrosprayed nanoparticles if chain entanglements do not occur.
These nanofiber mats have been investigated extensively as tissue engineering scaffolds, but they
can also be utilized as drug delivery vehicles when therapeutic agents are incorporated into the
electrospinning solution. The primary advantage of nanofibers as drug delivery vehicles is their
high surface area to volume ratio. Nanofibers dissolve or release dissolved drugs faster than simple
solution cast films of the same materials. For certain applications where immediate dissolution is
desirable, electrospun nanofibers can be an improvement over existing formulations. Another
aspect of nanocarrier drug delivery sometimes overlooked is storage stability. Many targeted
nanocarrier vehicles are not stable for long periods of time at physiologic pH and room
temperature. This can result in major changes in drug potency if the carrier must be delivered in
solution. Reliable storage of these vehicles is critical for clinical use, particularly when bioactive
groups are integrated. Nanofiber formulations offer the superior long term stability of other dry
dosage forms such as powders, but they are easier to handle and measure.
9

Research into electrospun nanofibers as drug delivery vehicles is fairly new, but has steadily
progressed over the last decade to include a broad range of therapeutic agents and applications.
Over the same period, parallel experimental and theoretical studies have revolutionized our
knowledge of the electrospinning process, and how to control parameters to produce desired fiber
morphologies. Considerable hardware advancements have occurred as well, in terms of both
complexity and efficiency of the machines. Coaxial needles can produce core-shell fibers with
different polymers, possibly for tailored drug release rates. Rapid electospinning machines with
multiple spinnerets or even spinneret less systems produce large volumes of nanofibers in less
time, opening the door for commercial scale up. (Figure 1.5) Taken together, these studies suggest
electrospun nanofibers may see clinical application in the near future.

Figure 1.5: Large scale electrospinning. The Nanospider system uses a needless spinneret to
rapidly generate large quantities of nanofibers. Adapted from Niu.4
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Chapter 2
Dendrimer Application in Ocular Drug Delivery – A Literature Review5
2.1 Abstract
Existing methods of administering ocular drugs are limited in either their safety or efficiency.
Nanomedicine therapies have the potential to address this deficiency by creating vehicles that can
control drug biodistribution. Dendrimers are synthetic polymeric nanoparticles with a unique
highly organized branching structure. In recent years, promising results using dendrimer vehicles
to deliver ocular drugs through different routes of administration have been reported. In this
review, we briefly summarize these results with emphasis on the dendrimer modifications used to
target different ocular structures.
Keywords: dendrimer; ocular drug delivery; nanomedicine
2.2 Introduction
Delivery of therapeutic compounds to the eye remains one of the largest unmet needs in advanced
drug delivery research. The massive market for ocular drugs, and the deficiencies of current
delivery methods create a tremendous opportunity for developing novel materials to improve
patient outcomes and reduce costs.20,22,32 Existing treatments are generally inadequate because
both the structure and the function of the eye create significant hurdles to delivering therapeutic
compounds safely and efficiently. Delivery through systemic circulation would be the simplest
method for patients to self-administer, but drug transport to most ocular structures is very low or
isolated by specialized selective barriers.15 Topical delivery is straightforward and safe, but the
combined effects of low corneal permeability and washout by tear fluid make this route highly
inefficient as well.33 More invasive approaches such as direct intravitreal or periocular injections
are efficient, but unattractive from a safety and cost perspective. Finally, poor solubility and
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systemic side effects are problems with many ocular drugs independent of route of
administration.34
Despite the clear need for improved vehicles, an ideal solution has yet to be developed.
Nanoparticle-based drug delivery systems have been theorized and investigated for decades, but
only recent years have seen rapid growth in the application of these systems.35,36 Nanoparticles
fabricated from a wide range of materials including polymers (natural and synthetic), liposomes,
and polysaccharides have shown enhanced delivery of ocular therapeutics.19,26,37,38 Alternative
strategies such as in-situ polymerizing hydrogels and erodible inserts have been developed.39-42
The biodistribuition of these nanomaterials in ocular tissues allows them to serve as vehicles that
compared to simple drug solutions: 1) increase quantity of drug that reaches the target organ, 2)
increase the length of time the drug remains at the target organ, 3) reduce the quantity of drug in
off-target tissues.43
One class of polymers that has shown particular promise in ocular applications are dendrimers.44,45
These uniquely structured polymeric nanoparticles provide versatile platforms capable of
delivering the complete array of ocular therapeutics30. Dendrimer science is still in its infancy,
with the first synthetic molecules being synthesized in the mid 1980s46. Still, by this point some
level of study has been conducted using dendrimers with all available routes of ocular
administration (Fig 2.1). This review briefly discusses the key considerations when designing
dendrimers for ocular drug delivery as well as recent developments in the field. It also briefly
outlines possible future directions for dendrimer-based materials and the possible regulatory
hurdles that need to overcome.
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Figure 2.1: Dendrimer routes of ocular administration. Dendrimer based vehicles have shown
pre-clinical efficacy in delivering ocular drugs through multiple routes of administration. These
include 1) topical application, 2) injection into the vitreous humor, and 3) injection into the tissues
around the eye. The eye structure was adapted with permission from the copyright holder of this
work from https://en.wikipedia.org/wiki/Eye, retrieved March 1, 2017.
2.3 Anatomy and Physiology of the Eye
Both the underlying structure and ongoing physiologic processes in the eye create major barriers
to ocular drug delivery.47 The eye is divided into two major chambers—the anterior and posterior
segments. The anterior segment of the eye contains everything between the lens and the cornea
and is filled with a continuously circulating aqueous fluid. The posterior segment of the eye is the
portion between the lens and the choroid and it is filled with a more gelatinous fluid called the
vitreous humor. Anterior segment diseases such as corneal wounds, glaucoma, and conjunctivitis
are generally targeted with topical eye drops.48 Posterior segment diseases such as macular
degeneration and retinopathy cannot currently be treated with topical vehicles and require more
invasive techniques such as direct injections or surgical interventions. 49,50
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2.4 Routes of Administration
2.4.1 Topical delivery: Topical delivery of ocular drugs, virtually always in the form of saline eye
drops applied directly to the cornea, has the advantage of being the simplest route of
administration. For drugs directed at anterior segment diseases, such as intra-ocular pressure
lowering agents, these drops are a safe and cost-effective treatment option. However, these
therapies suffer from notoriously poor patient compliance due ultimately to the poor delivery
efficiency of eye drops.51-53 Even under ideal conditions, only around 5% of the drug placed on
the eye reaches the anterior chamber.54 Permeation though the tightly packed epithelium of the
cornea and sclera is slow for anything but the smallest, most lipophilic compounds.23 At the same
time, tear turnover is relatively rapid, with virtually all of the eye drop drained from the ocular
surface within 15 minutes after instillation.48 To counter poor delivery efficiency, eye drops must
either utilize higher drug concentrations or a more frequent dosing schedule. Both are burdensome
on patients in the form of even greater quantities of the drug in off-target tissues, often resulting
in side effects. Successful topical ocular drug delivery vehicles must then either increase the
permeation rate of their material across the cornea or prolong the residence time of the drug on the
ocular surface.40,55,56
2.4.2 Systemic administration: Systemic administration is not commonly used with ocular drug
therapies. Although it would solve some of the patient compliance problems of topical delivery
while remaining simple and inexpensive, efficiencies are even lower. In the anterior segment,
blood perfusion rate is incredibly low, even relative to the size of the tissue. The posterior segment
does have significant vascularization, but almost all of it is concentrated in the choroid and
separated from direct access to the retina by the blood-retina-barrier.57 While some compounds
can be delivered to the eye through systemic administration, the concentrations needed to achieve
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therapeutic efficacy often result in many of the same side effects observed with topical
administration.
2.4.3 Injections: The only highly efficient route of administering ocular drugs currently in practice
are intravitreal and periocular injections. Both of these methods deliver high doses of drug in a
tightly targeted manner, but they come with significant drawbacks. Intravitreal injections are the
most direct possible route to deliver drugs to the interior ocular structures, but they also carry the
greatest risk of damage to the eye because the needle tip is hidden during the procedure.21,58
Injections into the surrounding structures such as the periocular tendons minimize most of these
risks, but they are still highly invasive and expensive.59 Critically, these methods are not viable for
managing chronic diseases like glaucoma. Serious risk factors associated with an individual
injection are slight, but their chance of occurring rises greatly when injections are used repeatedly
and frequently. Strategies to improve ocular drug delivery injections focus mainly on building
extended release mechanisms that can act as long term drug reservoirs in situ and minimize the
necessary dosing regimen.
2.5 Dendrimers
The term ‘dendrimer’ refers to any polymer composed of repeating, regularly branching units. A
large number of chemically distinct dendrimer families have been synthesized, but very few have
been studied in depth. Only one, polyamidoamine (PAMAM) dendrimers have been
commercialized.46 The synthesis of PAMAM dendrimers begins with a central core molecule and
‘generations’ of branches are added in a series of sequential reactions (Fig 2.2). This reaction
scheme produces highly monodisperse, spherical nanoparticles. With each successive generation,
the radius of the particle increases linearly, while the number of terminal groups and molecular
weight grow exponentially.
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Figure 2.2: Dendrimer synthesis and structure. PAMAM generations 0.0-3.0, with half
generations omitted. Particle size grows linearly with each full generation, but molecular weight
and the number of surface groups increase exponentially.
This unique structure gives dendrimers a number of useful properties for drug delivery not shared
by linear polymers.60 Primarily, their well-defined core-shell architecture and narrow
polydispersity make bio-distribution more predictable and easier to control through modifications
to the terminal groups.61 Also, drugs and other therapeutics can be loaded onto the nanoparticle
through multiple modalities, such as direct conjugation, ionic interactions, or trapping in the core
of the particle.62 This versatility makes dendrimers highly adaptable platforms that can be designed
to carry a wide range of therapeutics to a wide range of targets.63 In ocular drug delivery research
groups have utilized this versatility to develop dendrimer based strategies for multiple routes of
administration (Table 2.1). While this review is focused primarily on PAMAM dendrimers
because they are the closest to clinical translation, it is important to recognize the growing body
of research on alternative dendrimer particles in ocular drug delivery. These include phosphorous,
carbosilane, and peptide based dendritic nanoparticles.64-67 As the science matures, these novel
structures may represent the future of dendrimer nanoparticle drug delivery vehicles.
2.5.1 Topical formulations: Topical application, being the most direct and simplest method of
ocular drug delivery, was the first route investigated with dendrimer-based vehicles.68 Cationic
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nanoparticles have shown efficacy as permeation enhancers for transepithelial drug delivery.18,69,70
PAMAM dendrimers are strongly cationic on the full generations when amine terminated (G3.0,
G4.0, G5.0, etc.), so logically they should increase corneal permeability when applied in aqueous
solution. Vandamme et al. undertook systematic studies on the corneal residence time of PAMAM
dendrimers with an in vivo rabbit model.71 They found residence time was highly dependent on
the generation and terminal groups on the particle. In general, larger and hydroxyl terminated
dendrimers showed increased corneal residence time and drug delivery efficacy in these tests. The
authors hypothesized this effect was dominated by the dendrimers interaction with ocular muscins,
which impede washout of the drug. Ex vivo corneal permeation experiments by Yao et al. several
years later also found improved drug delivery efficacy with increasing dendrimer generation, but
they attributed this instead to greater disruption of corneal epithelial tight junctions by the larger
(and more cationic) particles.72 Likely, both phenomena are at work and represent important
aspects of dendrimer based ocular drug delivery.73-75
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Table 2.1: Preclinical ocular drug delivery studies utilizing dendrimer vehicles.
Dendrimer

Drug

Reference

Topical Application
PAMAM (G1.5-4.0)

Pilocarpine & Tropicarmide

Vandamme et al.71

PAMAM (G3.5-5.0)

Puerarin

Yao et al.76

Carbosilane (G1.0-3.0)

Acetazolamide

Bravo-Osuna et al.65

PAMAM (divalent)

Sulfonamide

Richichi et al.77

PPI

Acetazolamide

Mishra et al.78

PAMAM (G3.0 gel)

Timolol & Brimonidine

Holden et al.79

Intravitreal Injection
PAMAM (G4.0-OH)

Fluocinolone Acetonide

Iezzi et al.80

PAMAM core micelle

S1R agonist

Zhao et al.81

PAMAM (G4.0-OH)

Triamcinolone Acetonide

Kambhampati et al.82

Subconjunctival Injection
PAMAM (G3.5)

Carboplatin

Kang et al.83

PAMAM (G3.5, 4.5)

Dexamethasone

Yavuz et al.84

PAMAM (G4.0-OH)

Dexamethasone

Soiberman et al.85

A similar but distinct strategy for utilizing topically applied dendrimers is to incorporate them into
in situ polymerizing gels. This approach relies on the same principle that prolonging corneal
residence time can improve drug delivery efficiency, given most drops are rapidly drained from
the ocular surface. Dendrimers are highly versatile gel forming agents (Fig. 2.3).86 There are
several potential strategies for fabricating mucoadhesive ocular hydrogels from PAMAM
dendrimers alone.24,87,88 The properties of these materials can be easily tuned by modifying
parameters such as the concentration of polymer in solution or the number of reactive groups
present. This is critical to controlling the drug release kinetics and total residence time of the gel.
Photocurable dendrimer-poly(lactic-co-glycolic) acid hydrogels were first developed and tested in
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2012 by Holden et al.79 During UV initiated polymerization, the loose network trapped
nanoparticles containing anti-glaucoma drugs, and slowly released them over a four day period.
Because the gel network was completely independent of the drug nanoparticles, this material could
easily be adapted to deliver different ocular therapeutics.

Figure 2.3: Dendrimer gelation strategies. Dendrimers can be modified with diverse array of
reactive groups to form hydrogels. Drug release from these materials can be further controlled by
dendrimer type and generation, spacer length, and the mechanism of drug loading.
2.5.2 Injectable formulations: Intravitreal injection has become an increasingly common method
of ocular drug delivery over the last 15 years.89 Several physiochemical properties of PAMAM
dendrimers can be modified to give them a very long residence time in the vitreous cavity.
Dendrimers of varying generations and drug conjugations have been studied utilizing this route by
several groups.11,80,84 Kambhampati et al. injected G4 PAMAM dendrimers conjugated with an
anti-inflammatory drug and showed the conjugates selectively migrated to cells in the retinal
pigmented epithelium and activated microglial cells.82 These conjugates took advantage of
phagocytosis by activated inflammatory cells to prolong nanoparticle residence time, but in theory
other dendrimer properties could be used to develop long term vitreal drug reservoirs. Ex vivo
modeling studies have shown diffusion through the vitreous humor for nanoparticles the size of
dendrimers (<10nm) is dependent entirely on the surface charge of the particle.90-92 Highly cationic
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dendrimers should associate strongly with the anionic glycans of the vitreous humor, but the
cytotoxicity of these particles needs to be reduced with a passivating polymer such as
poly(ethylene glycol).93
Periocular injections offer many of the same potential benefits as intravitreal injections in terms of
highly efficient extended drug delivery, but with a less delicate injection site. To date studies on
periocular dendrimer injections have focused on subconjunctival delivery. This delivery site
protects the nanoparticles from washout by tear drainage, but still requires trans-scleral
permeation.94 Dendrimers in this application can be used to solubilize hydrophobic drugs and
provide a sustained release depot adjacent to the sclera.85,94,95 Sustained delivery vehicles have
many advantages from a patient compliance standpoint, but they can also make existing
therapeutics more effective. Kang et al. used PAMAM based aggregates to deliver the
chemotherapeutic carboplatin over a three-week period following a single subconjunctival
injection.83 The presence of the dendrimer network dramatically reduced the toxicity of the drug,
allowing for the use of an increased therapeutic concentration and corresponding reduction in
tumor volume.
Dexamethasone (DEX) is a particularly important ocular therapeutic with limited
bioavailability.96,97 While this glucocorticoid has been shown to effectively reduce inflammation
following eye injury, it is also rapidly cleared from both chambers.41 Recent studies by Yavuz et
al. and Soiberman et al. have utilized hydroxyl terminated PAMAM dendrimers to sustain DEX
delivery after subconjunctival injection.85,98 In the former, DEX delivery was directed toward the
posterior segment. In the latter, corneal inflammation was the target. Both studies showed
increased DEX delivery efficiency and longer residence time compared to simple solution
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injection. These two studies highlight the potential of dendrimer based injection systems as
promising strategies to treat both anterior and posterior segment diseases.
2.6 Conclusions & Future Directions
Even with a growing body of promising research, commercialization of dendrimer based drug
delivery systems remains slow. Dendrimers exist in a unique space where they are much larger
than traditional small molecule drugs and much smaller than traditional polymeric particles but
have biological properties similar to both. This has created a number of barriers to clinical approval
that industry and the regulatory agencies have yet to work out.99 First, the long-term safety of
dendrimers is a primary concern.100 Dendrimers are small enough (in most formulations) that they
will ultimately end up entering systemic circulation regardless of their initial route of
administration. 15,28 This makes overall safety an incredibly complicated area of study because the
local biodistribuition, toxicity, and complete biological activity of the vehicle must be determined
in many different tissues at many different time points.101 Even for unmodified PAMAM
dendrimers, there is a tremendous amount of work left to be completed. When you consider that a
principle advantage of dendrimers is how easy they are to modify with additional groups to control
biodistribuition, it is not surprising that creation of novel conjugates has outpaced deep study of
their systemic safety. The reliability and purity of commercial sources (or lack thereof), is another
bottleneck. Scale up for production and purification of complex conjugates is going to require
novel processes that are usually outside of the purview of the labs developing these technologies.102
There are also purely bureaucratic questions that remain unresolved. Chiefly, are dendrimer-drug
conjugates considered novel drugs or medical devices by the FDA? It would appear that most
dendrimer vehicles would classify as combination devices, but even in such cases the lead center
of the FDA is not clear. It seems these questions may continue until one PAMAM based vehicle
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breaks through to clinical approval and establishes precedent. Regulatory approval has been
swifter in Europe, where OcuSeal™, a dendrimer based cornea sealant was approved for human
use in 2009.
Despite these challenges, it is clear from recent research that dendrimers hold tremendous potential
as ocular drug delivery vehicles. Research groups around the world have been able to develop
dendrimer based materials which have shown improved drug delivery efficacy when applied
directly to the cornea as solutions or gels, as well as intravitreal, or subconjunctival injections. The
common theme throughout all these projects is that the unique structure of the nanoparticles make
them extremely versatile platforms for innovative scientists to adapt to overcome very different
barriers. As our understanding of the pharmacokinetics of the eye increase, the ways for
dendrimers and dendrimer based materials to improve drug delivery to this singularly complex
organ will inevitably increase as well.
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Chapter 3
Chitosan Nanofibers for Oral Insulin Delivery
3.1 Abstract
Purpose: In this work, we aimed at producing chitosan based nanofiber mats capable of delivering
insulin via the buccal mucosa. Methods: Chitosan was electrospun into nanofibers using
poly(ethylene oxide) (PEO) as a carrier molecule in various feed ratios. The mechanical properties
and degradation kinetics of the fibers were measured. Insulin release rates were determined in vitro
using an ELISA assay. The bioactivity of released insulin was measured in terms of Akt activation
in pre-adipocytes. Insulin permeation across the buccal mucosa was measured in an ex-vivo
porcine transbuccal model. Results: Fiber morphology, mechanical properties, and in vitro
stability were dependent on PEO feed ratio. Lower PEO content blends produced smaller diameter
fibers with significantly faster insulin release kinetics. Insulin showed no reduction in bioactivity
due to electrospinning. Buccal permeation of insulin facilitated by high chitosan content blends
was significantly higher than that of free insulin. Conclusions: Taken together, our work
demonstrates chitosan based nanofibers have the potential to serve as a transbuccal insulin delivery
vehicle.
Keywords: electrospun fiber, chitosan, insulin, transbuccal delivery
3.2 Introduction
Diabetes and other metabolic diseases are one of the most significant and growing health problems
in developed nations. As of 2011 almost 6 million Americans were already using exogenous
insulin to manage their diabetes, and of these patients almost all administer insulin through
invasive means, usually subcutaneous injection or infusion pump.103 Injections and pumps
however both have numerous associated side effects including but not limited to allergic reactions
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and lipohypertrophy.104 Importantly, neither is an optimal solution for pediatric patients, a rapidly
growing group.105,106 These problems and the poor patient compliance associated with them has
driven considerable research into alternative delivery methods, including oral, nasal, and rectal
therapies.13 There are obvious advantages of oral insulin delivery compared to injections, but
enzymatic and chemical processes in the GI tract limit the bioavailability of orally delivered insulin
to a degree where traditional drug delivery materials and methods are not viable.14 One possible
solution to this problem is to bypass the GI tract and hepatic portal system by absorbing insulin
through the oral mucus membranes.107-110 A material capable of enhancing rapid uptake of insulin
across the buccal mucosa would be able to combine the rapid and predictable dosing of
subcutaneous injection with the patient comfort of a pill.
The buccal mucosa itself is comprised of a layer of epithelial cells around 40-50 cells thick that
make up the inner lining of the cheeks.111 Besides its ready accessibility, several other aspects of
this tissue make it an attractive drug delivery route. The buccal mucosa is estimated to be as much
as 4000 times more permeable than skin epithelium.112 The area is highly vascularized, so absorbed
materials reach the systemic circulation rapidly. Also, cell turnover is very rapid, with complete
turnover every 5-8 days, limiting any acute cytotoxic effects caused by high drug concentrations
at the delivery site.112 Despite these advantages, hydrophilic drugs and especially peptides do not
usually diffuse across the mucosa fast enough to overcome the effects of continuous saliva flux
washing them out of the oral cavity. Mucoadhesive polymers are capable of holding the peptide at
high local concentrations long enough to allow diffusion to take place, but very few materials meet
the level of biocompatibility necessary to be used for long term insulin therapy.
Chitosan (CS), is one such material. Chitosan is the partially N-deacetylated derivative of chitin,
the major structural component of crustacean and insect shells. In addition to excellent
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biocompatibility comparable to similar structural polysaccharides, chitin is extremely naturally
abundant and therefore low in cost. For the most part though, it is chitin’s unique cationic character
that have make it an attractive research target in a number of biomedical applications; but this
work is hindered by chitin’s insolubility in most solvents. Despite this, processing into CS and
nanofabrication methods such as electrospinning can produce solid scaffolds for potential drug
delivery applications.113 CS based nanoparticles have been investigated for oral insulin
delivery,12,114-119 but there are physical limitations to handling and packaging nanoparticles.
Electrospun fibers on the other hand have many of the advantageous physical properties of
polymeric films and textiles while maintaining the high surface area to volume ratios of
nanoparticles.
In this work we have developed electrospun chitosan fibers using different amounts of
poly(ethylene oxide). The fiber diameter, mechanical properties, degradation rates, and insulin
release kinetics of these fiber blends were first measured and compared. To ensure insulin
entrapped in the fibers remains bioactive during the electrospinning process Akt-1 phosphorylation
in preadipocytes exposed to CS fiber scaffolds was quantified. An ex-vivo porcine model was used
to measure the buccal permeability of insulin released from each fiber blend. We believe this
material has the potential to serve as a cost effective platform for transbuccal insulin delivery.
3.3 Materials and Methods
3.3.1 Materials: Chitosan (CS, product#448869, batch#SLBH5874V), poly(Ethylene Oxide)
(PEO, Mw 900kDa, product#189456 batch#0741DD), and human insulin (INS, product#I2643,
batch#SlBK6641V) were purchased from Sigma Aldrich (St. Louis, MO). , 1,1,3,3,3-hexafluoro2-propanol (HFP) was purchased from Oakwood Chemicals (Estill, SC). Insulin ELISA assay kit
was purchased from Calbiotech (Spring Valley, CA).
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3.3.2 Electrospun fiber production: CS and PEO were dissolved in HFP at the concentrations
indicated in table 3.1. This solution was stirred for 72 hours at room temperature, allowing all
solid components to completely dissolve. INS was then added at 0.4 mg/ml and the solution stirred
for an additional 48 hours. The solution was electrospun into solid fiber mats with the following
conditions: 15 kV DC offset, 17 cm airgap, 18 ga. blunted needle, and 3 ml/hr flowrate. A typical
spinning run used 5 ml of solution and a round collecting mandrel (6.5 mm diameter). Scaffolds
were dried under vacuum 3 hours to remove residual solvent before any further testing.
Table 3.1: Electrospinning solutions content and final INS content.
Blend Ratio

CS conc. (mg/mL)

PEO conc. (mg/mL)

INS conc. (mg/mL)

CS:PEO20

8

2

0.4

CS:PEO33

8

4

0.4

CS:PEO50
8
8
0.4
3.3.3 Mechanical tests: Uniaxial tensile testing of electrospun scaffolds was performed as
previously described.120,121 Briefly, dog bone shaped punches of all fiber blends were taken
longitudinally oriented with the predominant fiber alignment. Scaffold thickness over the gauge
length was measured with precision calipers and the samples were loaded into a MTS Bionix 200
testing frame. Samples were uniaxially extended at 10mm/min until failure.
3.3.4 In vitro stability: Fiber stability under physiologic conditions was assessed quantitatively by
mass loss and qualitatively by SEM imaging. 10 mg fiber samples were incubated in 1 ml of PBS
at 37°C. At predetermined time points samples (n = 3) were spun down, and the degradation media
was removed. Scaffolds were then washed briefly in diH2O, lyophilized and weighed. One sample
from each time point was then mounted and gold coated for SEM imaging. SEM images were
taken on a JEOL LV-5610 scanning electron microscope in the Nanomaterials Core
26

Characterization facility at Virginia Commonwealth University. The diameters of fabricated fibers
were analyzed using ImageJ software, manually measuring at least 150 randomly chosen fibers in
each SEM image as previously reported.122
3.3.5 In vitro insulin release: 8mm punches of each fiber blend were weighed and hydrated in 10
ml of phosphate buffered saline at 37°C. At specified time points the tubes were vortex stirred
briefly and 100 μL samples taken of the release medium. A sandwich ELISA assay was then used
to quantify insulin concentrations.
3.3.6 Insulin bioactivity: To ensure insulin was not denatured during electrospinning Akt
phosphorylation of cells exposed to fiber release media was measured by western blot. 3T3-L1
preadipocyte cells were seeded in 6-well tissue culture plates and allowed to reach confluence.
Growth medium was removed and replaced with either fresh growth medium, insulin containing
medium (200 μIU/ml), or fiber release medium (CS:PEO20 0.15mg/mL for 6 hours). After
incubating for 10 minutes at room temperature, cells were lysed and western blot analysis was
performed as previously described.121 Briefly, cell lysates were separated on an SDS-PAGE gel
(10% w/v) and transferred onto a PVDF membrane using Bio-Rad Mini-Blot transfer apparatus.
The membrane was blocked for 2 h in Tris-buffered saline (TBS) containing non-fat dried milk
(5% w/v). Phosphorylated Akt-1 on the membrane was determined by incubating with a primary
antibody overnight at 4 ºC with shaking. The membrane was washed and then incubated in a
1:3000 dilution of a secondary antibody at room temperature for 1 hour in washing buffer (TBS
containing 0.5% w/v Tween 20). The specific antigen-antibody interactions were detected using
enhanced chemiluminescence. The membranes were then stripped and re-probed for total
expression of Akt-1 to use as the loading control.
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3.3.7 Trans-buccal permeation: Fresh porcine heads were purchased from Animal Biotech
Industries (Danboro, PA). Immediately upon arrival buccal membranes were removed and cleaned
of any loose connective or adipose tissue to a thickness of approximately 1mm. Buccal membranes
were loaded into a Franz diffusion cell (Permegear, Cranford, NJ) with the epithelial side facing
the donor chamber. The acceptor chamber was filled with 5.2 ml of PBS and maintained at 37⁰C.
A 10mm fiber sample was placed on the buccal tissue in the donor chamber and 0.5 ml of simulated
salival fluid (SSF) was added.123 At predetermined time points 100 μl samples were taken from
the acceptor chamber and the fluid was replaced with fresh PBS. The insulin concentration in the
acceptor chamber fluid was measured using ELISA assay as previously described. The
permeability coefficient, P, of the membranes was calculated using the following equation:
/

where dQ/dt is the steady-state slope of a cumulative flux curve, C is the loading concentration of
free insulin or sIPN GIF in the donor chamber, and A is the effective cross-sectional area (0.785
cm2) available for diffusion.118
3.4 Results
3.4.1 Electrospun fiber production: Electrospinning of neat chitosan was not successful due to the
lack of sufficient chain entanglements.124 The addition of PEO enabled production of smooth
fibers, but mixed beading due to fiber rupture was observed at polymer concentrations less than
20% (wt/wt). A mixed population of sub-micron (~200 nm) and larger (1-2 µm) fibers were seen
under SEM for high PEO content blends (figure 3.1). Mandrel shape was found to have a
significant impact on the distribution of insulin in the fiber scaffolds. Early experiments using a
flat rectangular mandrel showed wide variability in both the thickness of fibers deposited and the
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weight ratio of insulin trapped within the fibers. Both of these problems were corrected by
switching to a cylindrical collecting mandrel. Mechanical tests confirmed mechanical properties
of the fibers changed predictably with the composite ratios of CS and PEO. High CS content fibers
showed a significantly higher maximum stress but also reduced strain at failure compared to the
more ductile high PEO blends (table 3.2).
Figure 3.1. At least 20% high molecular weight polymer is necessary for stable fiber

formation. Poly (ethylene oxide) (Mw 900kDa) was added to dissolved chitosan electrospinning
solution in decreasing ratios. At 20% PEO solution content intermittent beading can be observed.
Scale bar 10μm.
Table 3.2: CS:PEO fiber mechanical properties.
Blend Ratio

Peak Stress (Mpa)

Strain at Break (%)

CS:PEO20

1.03±0.15

24.8±1.5

CS:PEO33

1.14±0.15

18.3±1.3

CS:PEO50

2.59±0.21

13.7±2.3

3.4.2 Physiologic stability: Mass measurements and SEM micrographs were used to evaluate how
fiber mats degraded when hydrated. These experiments showed CS:PEO fiber solubility in
physiologic conditions can be predicted by blend ratio (figure 3.2A). When hydrated fibers lose
most of their bulk mass of PEO within 15 minutes, but show no significant mass loss over the next
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6 hours. SEM images were consistent with these measurements, with significant changes in fiber
diameter from 0 to 15 minutes, but no changes for the duration of the degradation period (figure
3.2B&C).
3.4.3 In vitro insulin release: Short and long term insulin release under physiologic conditions was
measured for all fiber blends. Insulin release kinetics were highly dependent on the polysaccharide
content of electrospun fiber mats (figure 3.3). Higher chitosan content blends released insulin
significantly faster than lower chitosan content blends. By six hours CS:PEO20 and CS:PEO33
blends showed no significant difference and by 24 hours all fibers showed the same level of insulin
release.
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Figure 3.2. CS:PEO fibers dissolve slowly under physiologic conditions. 10mg samples of
CS:PEO fiber blends (n=3) were immersed in 5ml of PBS at 37⁰C. At predetermined time points
PBS was removed. Samples were then washed once with diH2O and freeze dried overnight. Mass
loss approximated PEO content (A). SEM micrographs showed no major morphological changes
in fibers over the degradation period (B, scale bar represents 50 μm). The average fiber diameter
measured in these micrographs also showed no significant changes within individual fiber blends
after hydration (C). (* denotes statistically significant difference between all groups p < 0.05)
3.4.4 Insulin bioactivity: 3T3L-1 preadipocytes treated with 6 hour release medium showed
significantly greater ratio of activated Akt than both negative (culture medium) and positive
(insulin containing) controls (figure 3.4). This indicates there is no loss of insulin bioactivity

31

caused by dissolution in HFP, electrospinning, or dry storage at room temperature for several
weeks.

Figure 3.3. Polysaccharide content controls insulin release kinetics. Fiber blends of different
chitosan:PEO ratios were immersed in PBS at 37⁰C. Insulin release was quantified at 15 minutes,
6 hours, and 1 day by ELISA assay. Various models were applied to fit the data. Curves
corresponding to the Ritger-Peppas equation are shown. CS:PEO20 fibers show the fastest release
profile, but there was no difference observed between blends at 24 hours.
3.4.5 Buccal permeation: High chitosan content is needed to induce trans-buccal insulin delivery.
Lower chitosan content blends CS:PEO50 and CS:PEO33 did not outperform dissolved insulin in
the 6 hour test, although all three groups saw negligible concentrations of trans-buccal insulin (less
than 1% of the total) (figure 3.5). CS:PEO20 fibers on the other hand delivered on average around
1/3 of their total insulin into the acceptor chamber after 6 hours. Permeability coefficients for the
lower chitosan content blends were 5 and 10 fold lower than naked insulin respectively while
CS:PEO20 fibers had a permeability coefficient over 10 fold higher than the same control (table
3.3).
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Figure 3.4. Insulin remains bioactive after electrospun fiber fabrication. 3T3-L1
preadipocytes incubated for 10 minutes in either fresh growth medium (control), 6 hour CS:PEO20
fiber release medium, or insulin containing media (7.98 μg/mL). Western blots of cell lysates were
run for p-Akt expression then stripped and re-probed for total Akt1 as loading controls. Cells
exposed to fiber release medium showed 3.5 fold higher p-Akt/Akt expression ratio than control
cells. (* denotes statistically significant difference from all other groups p < 0.05)
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Figure 3.5. Chitosan enhances buccal permeability. Insulin transport across the buccal
membrane was determined using a Franz diffusion cell. Measurements of the insulin concentration
of the acceptor chamber showed that membranes were largely impermeable to both dissolved
insulin and the lower chitosan blend ratios, with those groups delivering less than 1% of their total
protein over 6 hours. CS:PEO20 fibers however showed significantly higher insulin delivery over
the other groups at all time points over 2 hours. The permeability coefficient of the buccal mucosa
to each of these insulin compounds was calculated from the steady state flux region of the tests
and CS:PEO20 fibers showed around a 500 fold increase in permeability over the other fiber blends
and a 16 fold increase over naked insulin.
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Table 3.3: The insulin permeability coefficient and R2 of the cumulative flux curve for CS:PEO
fiber blends and naked insulin.
Blend Ratio

Permeability (10-5cm/s)

Q-R2

CS:PEO20

0.255

0.74

CS:PEO33

0.127

0.61

CS:PEO50

21.5

0.97

INS

1.27

0.76

3.5 Discussion
3.5.1 Synthesis: In this work we developed chitosan based electrospun fiber scaffolds for oral
insulin delivery. Chitosan nanoparticles have shown promise in a number of trans-buccal drug
delivery applications, but there are drawbacks to producing and utilizing nanoparticles in a clinical
setting. Electrospun fiber mats overcome many of these physical limitations, combining the rapid
production and workability of polymer films with the high surface area of nanoparticles. The
structure of chitosan however presents several problems for electrospinng. Solubility was the first
hurdle, as the solvent system used needed to efficiently dissolve chitosan without denaturing
insulin. A number of solvent systems have been investigated for electrospinning pure chitosan,
most commonly dilute acetic acid solutions but insulin is known to rapidly lose bioactivity at low
pH.125 Highly polar fluorinated solvents, such as HFP had previously been shown to readily
dissolve chitin and chitosan, as well as insulin without permanent structural changes.121,126 Neat
chitosan solutions in HFP can be readily electrosprayed into nanoparticles, but the rigid, charged
polysaccharide molecules do not readily form the chain entanglements that are needed for stable
fiber formation.127 High Mw PEO is readily electrospun, has excellent biocompatibility, and has
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been theorized to form hydrogen bonds with the amine groups on chitosan.124 These hydrogen
bonds encourage the chain entanglement that improve the overall spinning efficiency of the
polymer solution, but also significantly increases the fiber diameter of the final composite fiber
material. Preliminary work then focused on finding the minimum amount of PEO needed to
reliably form composite fiber scaffolds, and characterizing the material properties of different
CS:PEO blend ratios. 1:1 and 2:1 CS:PEO blends efficiently produced mats of continuous fibers
(figure 3.1A&B) as previously reported.128 At blend ratios greater than 4:1 fibers ruptured before
solidifying, a phenomenon known as beading. Beading was intermittent at 4:1 but could be
minimized by adjusting spinning parameters slightly (figure 3.1C).
Mechanical tests confirmed the composition of deposited fiber scaffolds matched that of the initial
spinning solution, and neither component was disproportionately lost during fiber formation. As
expected, increasing polysaccharide concentration in the spinning solution resulted in more brittle
fiber scaffolds, with an increased peak stress and decreased strain at failure (table 3.2).
3.5.2 In vitro stability and insulin release: For this work, it was desirable for fibers to adhere, swell,
and release loaded insulin but not to degrade significantly over the 3-6 hours they will be attached
to the application site. While both components of the scaffolds have very good biocompatible
properties it is always still preferable to limit the amount of polymer delivered into the circulation
in case there are any unknown tissue specific effects or unanticipated drug interactions.
Degradation experiments show when hydrated the different CS:PEO blends lose approximately
15, 20, and 50% of their bulk mass rapidly depending on the blend ratio, but there is no significant
mass loss over the next 6 hours (figure 3.2A). This suggests the majority of PEO incorporated into
the fiber mats dissolves rapidly leaving behind primarily chitosan fibers. Chitosan is stable enough
in aqueous solvents that no significant amount dissolves under the remainder of the test period and
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the fiber morphology remains constant (figure 3.2B), with no significant change in average fiber
diameter (figure 3.2C).
After material characterization, the insulin release kinetics of the fibers needed to be measured.
Although there are applications for long-acting insulin, for oral delivery it is not realistic to expect
a material to stay in place for more than a few hours. This makes it critical for a trans-buccal
delivery vehicle to have quick, predictable insulin release. With no significant degradation
occurring over the test period, the only possible mechanism of insulin release was diffusion out of
the fibers. Drug release by diffusion is directly proportional to surface area, so it was expected
that insulin release kinetics would be more rapid in mats with smaller fibers and this is what was
measured (figure 3.3). Measurements of SEM micrographs showed that while the average fiber
diameter within a group did not change over the degradation period, there were significant
differences between the groups at all points, with higher chitosan content in the initial spinning
solution resulting in smaller fiber diameters. At 15 minutes for example, this would have an equally
significant impact on the available surface area of the fiber mats since the volume of all samples
was the same. This process physically encapsulated insulin within the material, as opposed to a
surface binding technique, so a large surface area is critical to provide enough area for diffusion
out of the hydrated fibers to take place at a sufficient rate.
3.5.3 Bioactivity: The other major concern apart from the rate of insulin delivery was the
bioactivity of the insulin delivered. Dissolution in HFP, electrospinning, or dry storage could all
potentially affect the signaling potential of insulin by degrading or denaturing the protein. While
there are several major targets of the insulin signaling pathway that could have been measured,
one of the largest upstream targets of the insulin signaling cascade is protein kinase B (Akt1)
phosphorylation. Insulin causes Akt activation through insulin receptor substrate 1 (IRS1)
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phosphorylation, which activates phosphoinositide-3 kinase (PI3K). PI3K activates Akt1, which
in turn is responsible for many of the metabolic and mitogenic cellular responses to insulin
stimulation. For this reason cells exposed to bioactive insulin should contain a higher ratio of
phosphorylated Akt (S473) to total Akt compared to cells exposed to standard culture medium.
Adipocytes and preadipocytes in particular show a robust response to insulin, given their role as
the body’s major long term energy store. The response of the preadipocytes used in this study
showed that insulin dissolved in HFP and electrospun into chitosan fibers undergoes no significant
decrease in its bioactivity (figure 3.4).
3.5.4 Buccal permeability: Buccal permeability was the only property of these fibers tested that
did not show a dose-dependent relationship with polysaccharide content. In vitro experiments
suggested that the 4:1 CS:PEO fibers would have the highest short term insulin transport across
the buccal mucosa simply by diffusion. While this was observed, the trend did not hold true for
the other fiber blends. 2:1 and 1:1 CS:PEO fibers greatly underperformed the level of insulin
delivery expected following the in vitro experiments (figure 3.5). Hydrophilic compounds must
cross the epithelium via the paracellular route through tight junctions between cells. Chitosan is
known to enhance the permeability of membranes by transiently disrupting binding between tight
junction proteins.17 Furthermore, mucoadhesive materials hold dissolved compounds in much
higher concentrations directly adjacent to the epithelium, encouraging diffusion across the
membrane. While 4:1 CS:PEO fibers were able to deliver promising levels of insulin across the
buccal mucosa, the variation between samples was sub-optimal. It is possible this is a function of
the tissues samples used and not the fibers themselves. Permeability of the buccal mucosa is known
to vary widely throughout the mouth and in ex-vivo studies it can be problematic to keep
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application sites constant.111 Future work will need to confirm this result in a more reproducible
way by measuring the ability of CS:PEO fibers to lower blood sugar in a suitable animal model.
3.6 Conclusion
In this work we have developed electrospun Chitosan scaffolds designed for oral insulin delivery.
Poly(ethylene oxide) was added in different ratios to control fiber morphology and physical
properties. Degradation studies showed PEO dissolves rapidly under physiologic conditions but
fiber diameter does not change. Higher Chitosan:PEO ratio when spinning results in smaller fibers
and more rapid insulin release. Insulin released from electrospun fiber mats shows no impaired
bioactivity. 4:1 CS:PEO fibers have 16 times higher buccal permeability compared to free insulin.
Taken as whole, the results of this study suggest electrospun chitosan nanofibers can function as a
viable vehicle for oral insulin delivery deserving of further study.
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Chapter 4
Fast Dissolving Dendrimer Nanofiber (DNF) Mats as Alternative to Eye Drops for Antiglaucoma
Drug Delivery
4.1 Abstract
PAMAM dendrimers have been investigated as a potential platform for a number of ocular drugs,
but they are unstable when stored in aqueous solution. In this work we have developed dendrimer
based nanofibers (DNF) as a topical delivery vehicle for the glaucoma drug brimonidine tartrate
(BT). The safety and drug release kinetics of these nanofiber mats were evaluated in vitro and in
vivo using a normotensive rat model. DNF caused no toxicity at therapeutic levels in cultured cells
or ocular irritation in animal tests. Intra-ocular pressure response was equivalent between DNF
and BT solution in single dose tests, but DNF showed improved efficacy with daily dosing. This
study indicates electrospun nanofibers are a viable alternative to aqueous solutions as a method of
applying dendrimer drug vehicles to mucous membranes.
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Figure 4.1: Graphic abstract.
4.2 Introduction
Among the available routes of administration for ocular drugs, topical application is considered
the most desirable due to its combination of good tissue specificity and minimal invasiveness.129
However, delivery of drugs using conventional saline eye drops is severely limited by anatomical
and physiologic factors unique to the eye. Following administration, the entire drop is drained into
the systemic circulation in a matter of minutes, typically resulting in less than 5% of the drug
reaching the desired tissue.130 This increases costs and creates the risk of off-target effects. Patient
non-compliance is a major issue for glaucoma medications because most eye drops must be applied
at least two or three times per day, and they are difficult to administer. Combined, these drawbacks
lead many glaucoma patients to skip doses or even stop medication treatment.51,131 Estimates of
patient non-compliance vary, but electronic monitoring studies have consistently shown that a
major portion of glaucoma patients struggle to adhere to this dosing regimen for more than a few
weeks.52 For these patients, long-term treatment of high intraocular pressure (IOP) then relies on
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more invasive therapies such as surgical intervention. Despite the clear benefits of a more efficient
topically applied ocular drug delivery vehicle, significant research investment has so far borne no
optimal solution.39,132-134
A true replacement for saline eye drops would increase the bioavailability of therapeutic
compounds and reduce the dosing frequency while still having a simple application procedure and
minimal invasiveness. While conventional materials have failed to deliver these features, novel
nanocarriers such as dendrimers may offer new opportunities.73,79,87,135,136 Dendrimers are a class
of polymers with a well-defined branching structure. Each branch has a terminal end group that
can be functionalized with solubilizing polymers, targeting domains, imaging molecules, or
therapeutic compounds.136 The ability to incorporate these agents into a single nanoparticle make
dendrimers extremely flexible drug delivery platforms.137
Polyamidoamine (PAMAM) dendrimers have already demonstrated promise as vehicles for a
number of ocular drugs, although IOP lowering agents have not yet been studied.76,78,84,138 These
previous studies have delivered drug loaded dendrimers as nanoparticles in solution, where they
rely solely on the mucoadhesive properties of the polymer to extend residence time on the corneal
surface, but solid dosage forms such as erodible inserts extend corneal residence time using
mechanisms independent of particle charge.39 We also believe solid dendrimer based materials
will have other advantages over dendrimers in solution including superior storage ability and a
more reliable application procedure.
Previously, this lab has developed dendrimer based nanofibers.138 In this work, we sought to
further develop this material platform as well as investigate it as an ocular drug delivery vehicle.
To this end, modified PAMAM dendrimers were co-spun with polyethylene oxide and brimonidine
tartrate into nanofiber mats. The drug release kinetics of these fiber mats and the permeability of
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the drug across live corneas was quantified. The in vivo efficacy and biocompatibility of these
nanofibers was evaluated in a normotensive rat model by intra-ocular pressure measurement and
examination over a three-week trial. Disposition of dissolved dendrimers in various ocular organs
was determined by using fluorescently labeled nanofibers. Success of using these fiber mats for
glaucoma medications has been demonstrated by their ability to match or exceed the performance
of conventional saline eye drops in each of these tests.
4.3 Materials and Methods
4.3.1 Materials: All reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless
otherwise stated. PAMAM dendrimers (G3.0) were purchased from Dendritech (Midland, MI).
Hexafluoroisopropanol (HFP) was purchased from Oakwood Chemicals (Estill, South Carolina).
Cellulose dialysis membranes were purchased from Spectrum Labs (Rancho Dominguez,
California). Fresh rabbit eyes were purchased from Pel-Freeze Biologicials (Rogers, Arkansas).
4.3.2 G3.0-mPEG synthesis: PAMAM dendrimers generation 3.0 were conjugated with methoxy
polyethylene glycol (mPEG) (Mn=2 kDa) as previously described (Scheme 4.1).139 Briefly, mPEG
(1 equiv) was dissolved in tetrahydrofuran, followed by addition of 4-nitrophenol chloroformate
(NPC) (1.5 equiv) and triethylamine (TEA) (20 equiv). The reaction was run for 24 h at room
temperature and the salt was filtered off. The resulting mPEG-NPC was collected by precipitation
in diethyl ether and vacuum dried. PAMAM dendrimer G3.0 and mPEG-NPC were dissolved in
DMSO separately. The mPEG-NPC solution was added dropwise to the dendrimer solution at a
feed molar ratio of 16:1 for mPEG-NPC:G3.0. After 72 h, the solvent was removed under vacuum.
The resulting product G3.0-mPEG was purified via dialysis in deionized water using a 7000
MWCO dialysis membrane.
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Scheme 4.1: Synthesis and fabrication of DNF and BT/DNF mats. Following the synthesis of
PEGylated PAMAM dendrimer G3.0 (i.e., G3.0-mPEG), G3.0-mPEG is dissolved in HFP with
high molecular weight PEO in the absence or presence of the antiglaucoma drug BT and
electrospun into DNF or BT/DNF mats.
4.3.3 Electrospinning: HFP electrospinning solution containing G3.0-mPEG (120 mg/mL) and
polyethylene oxide (PEO) (Mn= 90 kDa, 20 mg/mL) was prepared. Brimonidine tartrate (BT) was
added to the electrospinning solution at the final concentration of 20 mg/mL prior to
electrospinning. One mL of electrospinning solution (with or without BT) was loaded into a
custom electrospinning machine and spun onto a rectangular aluminum mandrel using the
following parameters: 12 kV DC offset, 20 cm airgap distance, and a 1.5 mL/h solvent flow rate.
The obtained dendrimer nanofibers (DNF) and BT-containing DNF (i.e., BT/DNF) were degassed
overnight at atmospheric pressure (i.e., ATM degassing) and removed from the mandrel. Any
residual solvent was further removed under vacuum for 1 h (i.e.., vacuum degassing).
4.3.4 Fiber characterization: To assess fiber morphology, the samples of electrospun fiber mats
were mounted and platinum sputter coated for imaging using a Hiatachi SU-70 scanning electron
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microscope. Fiber mechanical properties were measured by using uniaxial tensile testing.
“Dogbone” punches (19.0×3.2 mm) were taken and deformed at a 10 %/min stain rate until failure
using an MTS Bionix 200 Mechanical Testing System.
4.3.5 In vitro drug release: Cellulose dialysis membranes (MWCO 3.5 kDa) were sealed on one
end and filled with 10 mg BT/DNF dissolved in 100 µL simulated tear fluid (STF).123 The tube
was placed in 2 mL of STF in a quartz cuvette. The concentration of the drug in the bulk solution
was quantified using absorbance of 320 nm light at 5 min intervals for 90 min. This procedure
was repeated for neat brimonidine solution (40 µg) and unmodified dendrimers mixed with an
equivalent drug amount.
4.3.6 Cornea permeability: Brimonidine transport across live corneas was measured using Franz
diffusion cells (PermeGear, Hellertown, PA). Corneas from fresh rabbit eyes were excised and
placed immediately into diffusion cells with the endothelial surface facing the acceptor chamber
and the epithelial surface facing the donor chamber. The acceptor chamber was filled with 5 mL
of glutathione buffered Ringer’s solution and the donor chamber with 100 µL of solution
containing 40 µg of the drug. The entire cell was placed in a water bath at 37 ºC. At various time
points 250 µL samples were taken from the acceptor chamber solution and drug concentration was
measured using a reverse phase HPLC equipped with a UV detector (96v:4v water:acetonitrile
mobile phase, 50×150 mm C18 column with 5 µm pore size).
4.3.7 In vitro cytocompatibility: NIH 3T3 fibroblasts were seeded into 96 well plates at a density
of 5000 cells/well and allowed to attach overnight. The cells were incubated with DNF at various
concentrations (on the basis of dendrimer) for an additional 24 h and assessed for viability using
WST-1 viability assay.
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4.3.8 IOP measurement: Normotensive adult brown Norway rats (Charles River Labs, Wilmington
MA) were used for all animal experiments in this study. They were housed under proper conditions
at Virginia Commonwealth University (VCU) and Medical University of South Carolina (MUSC).
The rats were kept under a cycle of 12-h light and 12-h dark for all the studies. All animal
procedures were approved by the VCU and MUSC IACUC. Rat IOP measurements were taken
with a TonoLab rebound tonometer (ICare, Finland) as described earlier.140 No anesthetics or
artificial restraints were employed during measurement. All measurements were taken by the same
operator at the same location using the hand corresponding to that eye. Time 0 for all experiments
(and baseline IOP readings) occurred at approximately 10 a.m. All IOP values reported represent
the average of at minimum 18 and maximum 30 individual instrument readings of each eye.
4.3.9 In vivo single dose response: Rats (n=4) were conditioned for at least 1 week to establish
baseline IOP. On the day of the experiment the animals had either 5 µL BT solution (40 µg), or an
equivalent dose of BT/DNF placed in the right eye (experimental eye). At time points 2, 4, 6, and
24 h post-dosing the IOP in both the experimental and contralateral eye was measured. Animals
were closely monitored for irritation and inflammation for the duration of the test.
4.3.10 Chronic use safety and efficacy: Normotensive rats (n=3) received 40 µg BT delivered via
saline solution or BT/DNF mat in the right eye (experimental eye) daily. IOP was measured daily
in both eyes immediately prior to drug administration. After 21 d, the animals were euthanized and
the eyes enucleated. Eyes were immediately fixed with Davidson’s solution and 5 µm sections
prepared. Sections were stained with hematoxylin and eosin and imaged.
4.3.11 Ocular disposition: Fluorescently tagged nanofiber mats were synthesized by covalently
linking fluorescein isothiocyanate (FITC) to G3.0-mPEG prior to electrospinning. Normotensive
rats (n=3) had fluorescently tagged nanofiber mats (without drug) applied to the right eye. At
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various time points, the animals were euthanized by carbon dioxide asphyxiation and the ocular
tissues harvested. Ocular globes were fixed in 4% paraformaldehyde, perfused with glucose, and
frozen for cryosectioning. Nanoparticle contents in the cornea, ciliary body, and retina were
visualized using fluorescence imaging.
4.3.12 Statistical analysis: The data are expressed as mean ±standard deviation. The single dose
response data were analyzed using one-way analysis of variance (ANOVA) for multiple
comparisons versus control group (time point zero) (Holm-Sidak method) in each treatment. Ttest was used for comparison of 3-week IOP reduction effect between BT saline solution and
BT/DNF. A p value <0.05 is considered statistically significant.
4.4 Results and Discussion
4.4.1 Synthesis and fabrication: The 1H NMR spectrum confirms that the partial modification of
G3.0 PAMAM dendrimers with mPEG was successful (Fig. 4.2). Integration of the peak at 3.72
ppm, the methane protons on PEG, and 2.4-3.5 ppm, assorted dendrimer peaks, showed the 16:1
molar feed ratio mPEG:G3.0 resulted in a final dendrimer surface coverage of approximately 40%.
PEG modification of PAMAM dendrimers has been widely studied by our lab and others, and has
a major impact on the physical and chemical properties of the nanoparticles. 31,60 A higher degree
of PEGylation (the percentage of surface groups modified) results in easier electrospinning by
lowering the charge density and breaking up the highly compact structure of dendrimers. Both of
these changes help encourage the polymer chain entanglements that differentiate electrospinning
nanofibers from electrospraying nanoparticles.141 These property changes also greatly increase the
biocompatibility of PAMAM dendrimers, which are cytotoxic in their unmodified form. However,
for drug delivery applications full PEGylation is not desirable as it neutralizes the dendrimers’
charge to a degree where cell permeation is inhibited, and it leaves no remaining surface groups
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for later modification.69 Approximately half PEGylation was selected for this project to balance
efficient nanofiber production and leave sufficient available groups to later adapt the material to
delivery alternate therapeutic compounds, targeting moieties, or imaging tags.

Figure 4.2: 1H NMR spectrum of G3.0-mPEG. Degree of PEGylation was determined by
integrating proton peak j (mPEG) and comparing with integration of proton peaks a-f, h, and i
(G3.0). The analysis determined around 40% of G3.0 surface groups were PEGylated.
Electrospinning parameters were designed to optimize efficiency while still producing dry
nanofibers. The most significant determining factor of fiber yield and morphology was expected
to be the quantity of high molecular weight PEO added to the electrospinning solution.142 While
1% wt/vol was sufficient to produce fibers a higher quantity of 2% was selected to ensure the final
material would dissolve rapidly when placed onto the ocular surface. Parameters such as flow rate,
mandrel speed, and DC offset were minimized at the given air gap distance to maintain a stable
pull of fibers. No preferred fiber morphology was directed with this approach. SEM imaging
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showed DNF mats had a low degree of alignment (Fig. 4.3A&B). The median fiber diameter was
around 2 µm for plain DNF with the distribution skewed toward smaller fibers (Fig. 4.3C). The
addition of BT decreased median fiber diameter to less than 1.5 µm and balanced the distribution.
Mechanical properties were not robust, with a modulus of just 1.81 and 4.97 MPa for DNF and
BT/DNF respectively, but these values were sufficient to cut and manipulate the mats without
breakage (Fig 4.3D).
4.4.2 In vitro assessment: Conversion of the tetrazolium salt WST-1 to formazan was used as an
indirect measure of cytotoxicity by quantifying the metabolic activity of viable cells. As the fibers
are not expected to have an impact on the mitochondrial activity of cells, this can be used to
approximate the number of living cells quickly. Preliminary experiments on fibroblasts showed a
50% reduction in cell viability at a concentration of 32.5 µM (IC50). To determine if this was
caused by residual electrospinning solvent another batch of fibers were dried by vacuum oven prior
to testing. It’s IC50 increased by 67% to 54.2 µM (Fig. 4.4). This is well above the expected
maximum concentration in vivo (~30 µM), given the BT loading concentration and approximate
volume of rat tear fluid. Because of this finding, all samples later used in animal experiments were
first vacuum dried.

49

Figure 4.3: DNF characterization. (A) High magnification electron micrographs of DNF and
BT/DNF. (B) Histograms of fiber measurements show BT caused an overall decrease in fiber
diameter. (C) Uniaxial tensile testing shows BT/DNF has higher elastic modulus, peak stress, and
strain at break than DNF.
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Figure 4.4. DNF cytotoxicity. NIH 3T3 fibroblasts were incubated with varying concentrations
of DNF for 24 h and cell viability measured via WST-1 assay. Degassing fibers under vacuum
(vacuum degassing) was shown to be more efficient in removing residual electrospinning solvent
and increasing DNF cytocompatibility than degassing fibers at atmospheric pressure (ATM
degassing).
As proof of concept before animal testing, the release kinetics of BT from DNF mats was evaluated
under static in vitro conditions, as well as permeation using ex vivo rabbit corneas. Static BT
release due to diffusion was determined by the interaction of the drug with G3.0-mPEG in solution.
Release was significantly slower from G3.0-mPEG fibers compared to both neat BT solution and
unmodified G3.0 dendrimers (Fig. 4.5). Due to the number of constituents present, there are
several mechanisms which may be responsible for this result. Slowed drug release in the G3.0
group indicates there is some interaction between PAMAM dendrimers and BT in solution. This

51

may be with the terminal or core groups on the polymer. More importantly, the PEGylation of the
dendrimers and the addition of PEO to the fibers appear to form a loose network in solution.

Figure 4.5: In vitro brimonidine release. BT delivery vehicles were dissolved and drug diffusion
across a 3.5 kDa dialysis membrane was measured for 90 min. Unmodified dendrimers and DNF
slowed initial drug diffusion in STF. DNF further slowed the rate of drug release for the entire
duration of the test.
Corneal permeability was investigated in an ex vivo rabbit model. Dendrimers have previously
been shown to increase permeability of epithelial cell layers, but BT eye drops have a relatively
high corneal permeability compared to most ocular drugs.70 Typical permeability coefficients for
brimonidine range between 2.1×10-7 and 3.6×10-7 cm/s.23 At the doses used in our tests G3.0mPEG fibers had no difference in permeability compared to brimonidine solution and all groups
agreed with the literature values for live rabbit corneas (Table 4.1). While increased permeability
would be beneficial to drug delivery efficiency, it is also known to cause numerous potential
problems, most commonly irritation.55 The fact that DNF did not affect corneal permeability
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indicates that they are not disrupting the structure of the native epithelium, an important
consideration for the long term biocompatibility of the material.74,143
Table 4.1: Permeability coefficient of rabbit corneas to brimonidine.
Formulation

P (10-6 cm/s)

Q-R2

BT solution

6.90

0.93

BT/G3.0

7.77

0.97

BT/DNF

6.43

0.91

Figure 4.6: In vivo single dose response. Brown Norway rats (n=4) received a single dose of BT
via saline eye drops or DNF topically. One dose of BT/DNF and one dose BT saline eye drops are
equivalently effective in reducing IOP response (* indicates significantly different, P<0.01).
4.4.3 In vivo efficacy and safety: In vivo experiments indicate BT drug delivery efficiency may be
improved by DNF, but the effect is difficult to capture in normotensive animals. Drug efficacy was
equivalent between DNF and saline eye drops in terms of single dose IOP response (Fig. 4.6). In
those tests, both formulations induced an approximately 2 mmHg (~15%) drop in IOP at 2 h,
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followed by a rebound above baseline at 6 h, and finally a return to baseline values by 24 h. While
DNF values were slightly lower than eye drops at all these time points, the difference was not
significant. It took several days of repeated application to achieve a differential effect with DNF.
The nature of IOP measurement on fully conscious animals produces considerable noise, but over
the three-week test period DNF experimental eyes recorded significantly lower average pressure
values than conventional eye drops. This result held when measurements were normalized to the
contralateral eye, individual eye baseline IOP, or both (Fig. 4.7). Taken together, these results
suggest DNF mats deliver BT with a similar efficiency to conventional eye drops with each
individual dose, but over repeated applications they build an additive effect, and are able to achieve
a significant drop in IOP using a sub-therapeutic drug dosage.
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Figure 4.7: In vivo 3-week daily dose response. Brown Norway rats (n=4) received a daily dose
of brimonidine via saline eye drops or DNF for three weeks. IOP was recorded immediately prior
to drug application. Values expressed are the difference between the experimental and contralateral
eyes after normalizing individual eyes to baseline levels. The dash lines represent the mean IOP
reduction values. DNF was able to sustain reduced IOP over the test period compared to saline eye
drops (# indicates significantly different, P<0.001).
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Figure 4.8: Ocular histopathology of chronic DNF application. Brown Norway rats (n=3)
received a single dose of BT via saline eye drops or DNF every 24 h for 21 days. No changes in
cornea morphology could be observed between the experimental groups. Other ocular structures
such as the ciliary body and retina showed the same result.
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Figure 4.9: Ocular disposition of DNF. Brown Norway rats (n=3) received a DNF-FITC mat
topically in the right eye (experimental eye) while the left eye received no treatment (contralateral
eye). Animals were euthanized at 2 or 24 h and the ocular tissues harvested and immediately
processed for cryosectioning. Fluorescent imaging of sections from various ocular organs showed
most dendrimers were flushed from the cornea in 24 h. Over the same time period, FITC-G3.0mPEG accumulated in the ciliary body of the experimental eye.
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In vivo ocular tolerance of DNF was excellent. DNF dissolve virtually instantly (<1s by video
analysis) Animals reacted noticeably less to direct DNF application than BT solution. No
outwardly visible signs of irritation or inflammation, such as redness, excessive blinking, or ocular
discharge were observed in any animals in the single dose response experiments. During the
chronic use trial several of the animals exhibited known side effects of BT in the experimental eye
by the second week, namely redness of the surrounding skin. Histopathology of these eyes showed
no gross morphological changes in the eyes exposed to either BT solution or DNF (Fig. 4.8). Taken
together, DNF appears to be a safe material for ocular applications.
A potential mechanism for this additive effect can be found in the results of the disposition
experiments. Fluorescence images indicated that while few dendrimers could still be observed in
the cornea 24 h after fiber application, quantities in the ciliary body had noticeably increased
compared to eyes harvested just 2 h after fiber application (Fig. 4.9). This means in the chronic
use trial, some of the previous day’s dendrimers were still present in the target organ when that
day’s BT was at its peak concentration. If these latent dendrimers were able to increase the
residence time of that next dose of BT, it could account for the gradual increase and plateau in
potency that we observed. It also agrees with the response of the contralateral eye, which saw a
slight IOP drop from baseline in the eye drop group, but no change with DNF. If the dendrimers
are holding the drug closer to the site of application, then they may be able to reduce the bleedover effects common with BT.
Other phenomenon could also be responsible for the result. The ocular bioactivity of topically
applied PAMAM dendrimers themselves is somewhat unknown, but no strong effect has been
detected in the limited studies conducted to this point.68,71,77,144 It could also be that fiber
application is simply more reliable. Great care was taken to ensure that drug dosage was consistent
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between the groups (as confirmed by HPLC), but eye drop instillation is prone to inaccuracy in
both animals and humans. Since the fibers are applied dry it is easy to ensure that all of the material
successfully makes it into the eye, where it is not uncommon for some amount of a drop to spill
onto the face of the animal. This could point to a possible pediatric or veterinarian use for the
material, where topical drops problematic not just for their low efficiency, but also their awkward
application procedure. Other groups have seen similar improved efficacy with solid dosage forms
in veterinary glaucoma treatment.134
4.5 Conclusion
In this work, electrospun dendrimer based fibers have been developed as a novel vehicle for topical
administration of therapeutic compounds to the eye. The drug delivery efficacy and ocular
tolerance of the material has been evaluated in vitro, ex vivo, and in vivo using a model ocular
drug, brimonidine tartrate. Results were equivalent between DNF and saline eye drops in terms of
safety and single dose drug delivery efficacy, but DNF outperformed the control when applied
daily. Disposition experiments showed dendrimer accumulation in the anterior chamber,
suggesting the platform can function as a powerful ocular drug delivery vehicle with further study
and development. The studies suggest that drug loaded dendrimer nanofiber mats can be a
promising alternative to drug saline eye drops.
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Chapter 5
PAMAM Dendrimers for Improved Timolol Delivery
5.1 Abstract
Anti-glaucoma drugs suffer from poor bioavailability due to low solubility and corneal
permeability. In this work we have sought to improve these properties of the beta-blocker timolol
by direct coupling of the active group on timolol to a generation 3.0 PAMAM dendrimer via a
PEG spacer to form dendritic timolol (DenTimol). Preliminary animal tests indicate that DenTimol
retains bioactivity similar to timolol after grafting. Ongoing experiments are evaluating the corneal
permeability and ocular disposition of this material. Future experiments will focus on further
characterizing the PK/PD profile of this coupled drug.
5.2 Introduction
Ocular hypertension, or elevated intra-ocular pressure (IOP) is a chronic condition that can lead to
degenerative and irreparable vision loss. There are multiple causes of ocular hypertension, but in
all cases the immediate aim of treatment is to lower IOP back to normal levels and prevent further
progression of the disease. Pharmacologic therapies are usually the first treatment option
employed, because they are considerably cheaper and less invasive than surgical intervention
options. Beta-adrenergic antagonists, colloquially referred to as β-blockers, reduce IOP by slowing
production of aqueous humor. Timolol maleate is a β-blocker developed in the 1970s.145 It
selectively binds to adrenergic receptors in the ciliary body, making it a more potent IOP lowering
drug than other β-blockers.146
Despite the existence of these potent IOP lowering drugs, glaucoma remains the second leading
cause of preventable blindness worldwide.22 This is because the impact of current treatments are
severely limited by inefficient drug delivery systems. For example, when timolol is delivered as a
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topical solution, only about 5% of the total drug at best makes it to the target organ with each
dose.48 Because of this, the period of time after a dose where the drug is within its therapeutic
concentration window in the anterior chamber is narrow, between 4-5 hours.147,148 The remaining
volume is flushed into systemic circulation where it can cause cardiovascular side effects of
varying severity.33,149,150 Vehicles that can improve the delivery efficiency of this drug could
reduce either the necessary concentration or dosing regimen, representing a significant
improvement in the clinical management of glaucoma.
The study of nanoparticle vehicles to improve the bioavailabilty of topical ocular drugs has
received considerable research interest over the last decade.35,36,56 Most drug loss from eye drops
occurs due to pre-corneal mechanisms.48 Generally, most drugs penetrate the corneal epithelium
slowly relative to the rate of tear drainage and turnover.151 Poly(amidoamine) (PAMAM)
dendrimers are polymeric nanoparticles with the potential to overcome these factors because they
have appropriate size and mucoadhesive character to both slow washout and increase cornea
permeability.30,152 PAMAM dendrimers have been complexed with other ocular therapeutics,
resulting in improved drug deliver efficacy, but these methods rely on the formation of metastable
dendrimer-drug complexes.76,78,82,98 To date, studies using directly coupled dendrimer-drug
conjugates have not been carried out with ocular therapeutics, but the technique has shown promise
in the field of targeted chemotherapy.153
The purpose of this study is to modify dendrimers with a prodrug of the IOP lowering drug timolol
in order to increase the bioavailability of the compound. The safety and efficacy of this material
will be measured relative to conventional timolol eye drops.
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5.3 Methods and Materials
5.3.1 Synthesis: (S)-4-[4-(Oxiranylmethoxy)-1,2,5-thiadiazol-3-yl]morpholine (OTM, Toronto
Research Chemicals, Toronto ON, cat#O847080) was dissolved in DCM and reacted with an
equimolar amount of 5kDa Amine-poly(ethylene glycol)-carboxyl (PEG, JenKem, Plano TX) for
3 hours at room temperature. The product was recovered by rotary evaporation and purified by
dialysis in water with a 3.5kDa dialysis membrane and lyophilized. OTM-PEG was then coupled
to Generation 3.0 poly(amidoamine) dendrimers (G3.0, Dendritech, Midland MI) by dissolving in
DMSO and reacting overnight in the presence of a large molar excess of N-(3Dimethylaminopropyl)-N′-ethylcarbodiimide

hydrochloride

and

N-Hydroxysuccinimide

(EDC/NHS). The product was purified by dialysis with a 7.5 kDa dialysis membrane for 48 hours
and lyophilized (Scheme 5.1).
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Scheme 5.1: DenTimol synthesis. (Clockwise from top right) OTM was coupled to amine-PEGcarboxyl by spontaneous ring opening reaction. OTM-PEG was coupled to G3.0 dendrimer by
EDC/NHS mediated crosslinking reaction.
5.3.2 NMR spectra: 1HNMR was performed using a Bruker 400 MHz NMR to verify successful
conjugation. OTM spectra was obtained in deuterated methanol. OTM-PEG and G3-PEG-OTM
spectra were obtained in D2O.
5.3.3 HPLC analysis: Reaction products were separated using a Waters reverse phase HPLC
system equipped with a UV detector (50v:50v water:acetonitrile mobile phase, 50×150 mm C18
column with 5 µm pore size). UV absorbance was monitored at 220 and 300nm.
5.3.4 Ex vivo permeability: Corneal permeability was determined using Franz diffusion cells
(PermeGear, Hellertown, PA). Corneas from fresh rabbit eyes were excised and placed
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immediately into diffusion cells with the endothelial surface facing the acceptor chamber and the
epithelial surface facing the donor chamber. The acceptor chamber was filled with 5 mL of
glutathione buffered Ringer’s solution and the donor chamber with 100 µL of solution containing
1 mg G3-PEG-OTM or and equimolar amount of OTM and OTM-PEG intermediate. The entire
cell was placed in a water bath at 37 ºC. At various time points 250 µL samples were taken from
the acceptor chamber solution and drug concentration was measured using reverse phase HPLC as
described in section 5.3.3.
5.3.5 In vitro cytotoxicity: NIH 3T3 fibroblasts were seeded in a 96 well plate at 5000 cells per
well and allowed 24 hours to attach. OTM, PEG-OTM, and G3-PEG-OTM solutions of various
concentrations were added and incubated for 24 hours. A WST-1 formazan conversion assay
(Roche BioTech, cat#05015944001) was run according to the manufacturer’s protocol to quantify
viable cell numbers.
5.3.6 In vivo efficacy: Rat IOP measurements were taken with a TonoLab rebound tonometer
(ICare, Finland) as described earlier. No anesthetics or artificial restraints were employed during
measurement. All measurements were taken by the same operator at the same location using the
hand corresponding to that eye. Time 0 for all experiments (and baseline IOP readings) occurred
at approximately 10 a.m. All IOP values reported represent the average of at minimum 18 and
maximum 30 individual instrument readings of each eye.
Drug efficacy was measured in vivo by dosing brown Norway rats (n=4) in the left eye with 10 µL
timolol solution or equivalent G3-PEG-OTM solution. IOP was measured using a TonoLab
rebound tonometer (Icare, Finland) at various time points in both eyes. Change in IOP was
referenced to the contralateral (right) eye. A one-way t-test was performed to determine significant
decreases in IOP (α≤0.05).
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5.4 Results and Discussion
5.4.1 Synthesis & characterization: 1HNMR spectra indicated that OTM coupling to PEG was
successful due to the presence of peaks at 3.79 and 3.54 ppm. HPLC of the raw product from this
reaction produced multiple elution peaks, but dialysis removed free drug successfully (Fig 5.1).
HPLC output after purification showed a single DenTimol elution peak about 1 minute after
injection, indicating the absence of free drug in the final conjugate. Analysis of the final
nanoparticle spectra determined a PEG:G3.0 ratio of approximately 22:1, or 61% surface coverage
(Fig 5.2). While OTM specific peaks cannot be resolved on the full DenTimol H+NMR spectra
due to the relatively large mass of dendrimer and PEG present, is assumed at this time that no loss
of drug has occurred during the PEG:G3.0 coupling step. More detailed mass spectrometry testing
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will be needed to verify this assumption.
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Figure 5.1: HPLC of reaction products. Purified DenTimol product shows no elution peak at
3min, indicating no free prodrug present.
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Figure 5.2: DenTimol NMR spectra. OTM proton peaks at 3.79 and 3.49 ppm (h & i) were still
present on the final nanoparticle NMR spectra, but were obscured by overlapping dendrimer
signals. Integration of PEG peak f and dendrimer peaks a-d was used to estimate drug loading
quantity.
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5.4.2 In vitro assessment: OTM has similar bioactivity to timolol and is non-toxic, but it is
hydrophobic, with even lower ocular bioavailability than timolol maleate.154 Coupling to a linear
hydrophilic polymer such as PEG, can solubilize the compound, but as our corneal permeability
results show this structure does not readily penetrate the cornea (Fig 5.3). PAMAM dendrimers
are also highly hydrophilic, but they are also compact and strongly cationic. This unique
architecture allows them to penetrate the cornea relatively easily even when covered with drug
moieties. Direct coupling of OTM to dendrimer without a spacer is theoretically possible, and
would likely result in an even higher level of bioavailability.155 However, without the flexibility
provided by the polymeric linker it is likely bioactivity of each prodrug moiety would be reduced,
either due to steric hindrance from the dendrimer, or folding in of the dendrimer end groups
towards the core of the molecule.62
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Figure 5.3: Corneal permeability. Permeation rates (by percentage) were equivalent for
DenTimol and OTM. PEG-OTM intermediate was not able to penetrate ex vivo corneas.
Use of the spacer also has another benefit. PAMAM dendrimers are known to be cytotoxic at
micromolar concentrations, but covering a large portion of the particle’s surface with PEG chains
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erases most of this effect.31 Indeed, our cytotoxicity results indicate that DenTimol particles show
no signs of cytotoxicity up to 10µM, but due to the high drug payload per dendrimer this is many
times higher than the effective drug concentration necessary to match therapeutic timolol
concentrations (Fig 5.4). This suggests drug payload may be able to be reduced somewhat without
hurting the safety of the particle. A lower degree of PEGylation would increase the charge of the
particle and presumably the corneal permeability.

Figure 5.4: Cytotoxicity. DenTimol conjugate shows no increased toxicity over OTM prodrug at
the same effective drug concentrations. Red line indicates estimated maximum therapeutic
concentration.
5.4.3 In vivo safety and efficacy: Animal tests showed that G3-PEG-OTM lowers IOP when
administered in a topical drop. IOP in the experimental eye dropped by an average of 7.3 mmHg
(~30%) (Fig 5.5). Unfortunately, while the use of fully awake animals provides a more
philologically relevant model, it also produces more noise in the measurement of pressures by
rebound tonometry. This noise makes it unclear at this point if potency is increased over timolol.
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The IOP response profile observed for DenTimol is roughly equivalent to literature reported values
for timolol in rodents.156 The effect of chronic application has also not yet been studied. Clinical
IOP lowering treatments rely on an additive effect of repeated drug dosing. We expect, at
minimum, for this phenomenon to be present with DenTimol treatment, if not greater due to the
mucoadhesive quality of the particles. Ongoing and furfure work is also focused on building a
more complete pharmacokinetic profile for the compound. We believe this material can extend the
therapeutic window for timolol sufficiently to reduce dosing frequency to once a day or less. If
this is not achieved with the current synthesis strategy, there are numerous options for further
dendrimer modifications including changes to dendrimer generation, PEGylation density, and even
active targeting ligands with mucin selectivity.25
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Figure 5.5: Single dose IOP response. DenTimol induced a significant drop in IOP at 8 hours,
indicating similar bioactivity to timolol (n=4). (* indicates statistically significant decrease in
experimental eye IOP p≤0.05)
5.5 Conclusions
In this work, we have coupled a prodrug of the selective β-blocker timolol to a PAMAM dendrimer
via a flexible spacer. This new conjugate is highly water soluble and shows no signs of toxicity or
ocular irritation in vitro or in vivo. Administration of the conjugate to normotensive rats results in
a mean 30% decrease in IOP at 8 hours compared to the contralateral eye. Optimization of drug
loading and spacer length may be able to further improve this response. Detailed pharmacokinetic
work is ongoing.
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Chapter 6
Conclusions and Future Directions
6.1 Summary
The background and significance of transmembrane drug delivery were discussed in chapter 1.
The body possesses mucous covered membranes at several external sites, including the eyes,
mouth, nose, and reproductive organs. Drugs can be delivered directly across these membranes to
avoid clearance mechanisms in the liver and kidneys, but there are special considerations to ensure
that drug permeation is quick, efficient, and safe. After application, liquid flow flushes drug away
from the desired site before they can penetrate the epithelial cell layer that makes up these
membranes. The cornea is a site where topical drug delivery is particularly inhibited by these
processes, but it is also a location where transmembrane drug delivery can have the biggest clinical
impact.
Nanotechnology approaches to improving transmembrane drug delivery were the next topic
covered. Nanocarriers, which are particles less than a micron in diameter, can be used as drug
delivery vehicles that change drug biodistribuition to concentrate it at the desired site of action.
Many classes of these carriers with unique structures are under investigation, but in general
properties like size, charge, and functional groups are used to direct vehicle distribution.
Dendrimer based vehicles are the major focus of this work. Dendrimers are spherical polymeric
nanoparticles with an organized branching structure. Because they are compact and easy to
functionalize, they are an ideal vehicle for transmembrane drug delivery.
Most of these nanocarriers are usually delivered as particles in solution, but solid formulations
have some special utility. Generally, solid materials have superior storage stability to solutions
under ambient conditions and are easier for patients to apply reliably. In these studies,
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electrospinning was used to turn particle nanocarriers into dry nanofiber mats. These fibers hydrate
very quickly due to their large surface area. When compared to simple films of the same materials,
this increases drug release rate and decreases dissolution time.
Literature examples of dendrimers being used in ocular drug delivery were documented and
discussed in chapter 2. Broadly, these approaches were divided into topical and injectable
formulations. Topically applied dendrimer based ocular drug delivery vehicles included simple
approaches such as the one taken by Yao et al. where dendrimers of various generations were
added to a drug solution and applied to the eye.76 They also include more complex strategies such
as the one employed by Holden et al. where dendrimers used to form an in situ polymerizing gel
on the corneal surface.79 Both of these approaches resulted in increased corneal residence time for
the drug, and ultimately enhanced efficacy. Injectable formulations used a similar variety in
strategies, but one notable result was obtained by Kambhampati et al., who used hydroxyl
terminated dendrimers to selectively target areas of active retinal inflammation. The breadth of
these projects and the diverse array of ocular therapeutics delivered shows the flexibility of
dendrimers as a drug delivery platform that can be adapted for ocular drug delivery.
Chapters 3, 4, and 5 focused on nanocarrier materials developed at this lab for transmembrane
drug delivery. The chitosan nanofibers developed in chapter 3 were an extension of earlier work
completed by Aduba et al. on gelatin based nanofibers.120 In that study, nanofiber patches were
used to deliver insulin across the buccal mucosa. However, the material dissolved too quickly to
be clinically viable. Xu et al. improved this solubility by using a synthetic crosslinker to stabilize
the fiber network.121 This crosslinker was potentially toxic though, so in the present study, we
produced insulin containing nanofibers from the insoluble polysaccharide chitosan.6 Drug release
kinetics from these fibers illustrated a key advantage of using nanofibers as drug vehicles. High
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chitosan content blends produced fibers with a smaller average diameter. These materials therefore
contained a larger effective surface area and released insulin faster. While permeation studies
showed improvement over previous insulin delivery nanofiber patches, delivery rates are still too
slow for clinical use.
Chapters 4 and 5 are closely related dendrimer based ocular drug delivery projects. In chapter 4,
we demonstrated that dendrimer based nanofibers could function as a viable ocular drug delivery
platform, with modest improvement in IOP reduction over traditional eye drops in a normotensive
rat model. It is not yet clear if this result was due to the chemistry of the nanofiber mats or their
physical form. Ex vivo and single response data suggested that DNF improved drug delivery
efficiency very little relative to eye drops, but when applied daily they produced an additive effect,
plateauing after about 4 days. This may be due to the relative difficulty and inaccuracy of instilling
drug solutions into the eyes of conscious, unrestrained rodents. If true, this points to possible
application for nanofiber based materials as veterinary or pediatric ocular drug delivery vehicles.
Chapter 5 extended dendrimer based delivery of anti-glaucoma drugs to direct covalent
conjugation. A prodrug of the β-blocker timolol was attached via flexible spacer to a generation
3.0 PAMAM dendrimer. This novel conjugate retained the bioactivity of the prodrug while
increasing the solubility of the compound dramatically. Initial animal tests showed a dramatic and
prolonged reduction in IOP after just one dose. Ongoing experiments are determining the chronic
IOP response and safety of this conjugate. Initial attempts to electrospun this compound have been
unsuccessful, but further modifications are being attempted.
6.2 Discussion
6.2.1 Nanofiber patches as transmembrane drug delivery vehicles: The preceding studies have
focused largely on the pharmacokinetic benefits of topically applied drug delivery films, but thin
73

films offer many benefits for patient comfort and compliance as well. Rapidly dissolving dosage
forms have a long history of success as an alternative option for pediatric patients, but recent
developments have spurred interest in the technology for general use. They are easier to apply,
produce no choking hazard, and do not require water.157 It is also easier to scale down dosage than
with capsules or tablets, a critical feature for pediatric or veterinary use where patient weight can
vary widely. For these reasons and others, advanced thin film systems have seen increased research
interest and clinical application. The bulk of this work is for oral and dermal drug delivery, but
examples of ocular devices can be found as well.158-160
Drug release kinetics from these films can be very complex, depending on the properties of the
materials used. Layer by layer assemblies are commonly used to tailor release rates.160 For
transmembrane patches, the addition of extra layers can also be used direct drug release in the
direction of the epithelium. Especially for sites where mucous flow is very rapid, as in the case in
both the oral and ocular membranes, these devices can overcome one of the main limiting factors
to drug delivery, by isolating the permeation site from any washout. For example, the rate of tear
washout under a contact lens is estimated to be as low as 3%/min, compared to 16%/min for a
normal eye.161
6.2.2 Difficulties of Transmembrane Drug Delivery Models: A major hurdle to overcome when
developing thin film or semisolid drug delivery vehicles is the difficulty in developing relevant in
vitro and in vivo membrane models. Even though tremendous advancements have been made in
cell culture techniques, including liquid air interface systems, culture of epithelial cells into intact
membranes is difficult, and even the best constructs lack critical physiologic mechanisms. Ex vivo
systems fare better from a cell structure, but are highly dependent on sample quality and condition
as well as the particular test setup. For example, ex vivo cornea permeability experiments are a
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vital tool for exploring drug transport mechanisms, but the effect of tear flow are usually
completely absent. Given tear drainage is often the major limiting factor preventing drug
absorption, the ability of these models to predict clinical efficacy is debatable.162 New microfluidic
systems are attempting to improve on the conventional test setup, but their development is still in
the early stages.163
Animal experiments are the natural answer to these limitations, but they present their own
problems. Inter-species differences between animal models are an issue in all forms of biomedical
research, but there are special considerations with pharmaceutical research. The size of the
organism is a primary concern for pharmacokinetic experiments. As an example, mouse eyes are
too small to reliably quantify drug content in the aqueous humor for many therapeutics. For this
reason, larger rodent models such as rabbits are usually employed, but even still aqueous humor
volume may not be sufficient to measure some drugs. In addition to size, membrane anatomy and
physiology is very different in some animal species compared to humans. Rodents possess a
keratinized epithelium in their buccal membranes because they store food in tough cheek pouches.
The permeability of these membranes is many times lower than in mammals with a non-keratinized
buccal epithelium, so they are inappropriate model for trans-buccal drug delivery research. The
need to jump right to pre-clinical testing in large animal models such as pigs creates a significant
cost hurdle to developing these technologies.
Another, and perhaps the biggest difficulty in developing transmembrane drug delivery vehicles,
is the amount of unknown information on membrane physiology. Just in the last two years, it was
discovered that nanoparticle transport across the intestinal mucosa was highly dependent on food
intake.164 For years, these were thought of as mostly passive tissues, but increasingly science is
showing that these membranes are active barriers, responding to their environment. Until these
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kinds of active responses are better studied, they cannot be accounted for in drug delivery studies,
but nanocarriers may play a role in that as well. In October 2016, Henry et al. used fluorescently
tagged polystyrene nanoparticles to monitor nanoparticle diffusion though the vaginal mucosa in
real time.165 This study showed that anti-PEG antibodies could recognize and immobilize particles
though interactions with mucin chains. Not only is this an important discovery on an understudied
mechanism our bodies use to trap pathogens in mucous membranes, it could point toward new
techniques to develop mucoadhesive materials.
6.3 Future Directions
6.3.1 Layer-by-layer assemblies: As mentioned above, backing layers are one of the most common
methods used to improve transmembrane drug delivery devices, usually by preventing drug
diffusion in the apical direction and shielding the site of permeation from mucous flow and
washout. In chapters 3 and 4, electrospinning was used to fabricate nanofiber patches designed for
direct membrane application. In these studies fibers were deposited on a stainless steel collecting
surface until the mat was thick enough to be removed, but this does not necessarily have to be the
case. Rigid or flexible substrates can be affixed to the mandrel and used as a collecting surface for
nanofibers. This technique is commonly employed in tissue engineering applications where thin
or single layers of nanofibers are desirable.166 Drug delivery efficacy would likely be improved in
both of these materials by spinning onto impermeable supports. For chitosan insulin fibers,
deposition onto a backing film would be a simple method of improving drug delivery efficiency.167
With chitosan present as the mucoadhesive layer, this film need only to be impermeable to insulin.
For DNF, deposition onto disposable contact lenses is the most promising approach. Drug delivery
via contact lenses is not a novel idea, but applying a layer of quick dissolving nanofibers to only
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the basal side of the lens has not yet been applied. Eventually, it is likely that DenTimol delivery
could also be improved by this method.
6.3.2 Alternative ocular therapeutics: These vehicles are not limited only to the drugs covered thus
far. DNF in particular have the potential to serve as a broad delivery platform for a wide array of
ocular therapeutic compounds, from antibiotics to genes. Ocular inflammation in children is more
likely to be caused by infectious agents than inflammation in adults.168 Without early intervention,
these infections can have long term effects on the child’s vison. With younger children the risk of
permanent vison loss rises sharply,168 but so does the difficulty of administering eye drops. DNF
could serve as more comfortable antibiotic dosage form for these patients, analogous to chewable
oral tablets commonly prescribed for children. Specific to ocular pathogens, DNF have the added
benefit of the known anti-microbial properties of the dendrimers themselves.169
This is not to imply that electospinning alternative therapeutic compounds is a trivial process. As
seen in the morphology differences between DNF and DNF+BT additives to the electrospinning
solution, even in small amounts, can have a big effect on the fiber formation process. Surface
tension in particular is critical to fiber stability, so any drugs that impact surface tension may cause
fiber rupture, or dramatically increase the working voltage (reducing spinning efficiency).170
Compounds may also disassociate with the polymer during drying, forming crystals.171 Lastly,
strong electrospinning solvents such as HFP are not compatible with all therapeutics. Bioactivity
of more complex compounds such as peptides and genes cannot be assumed after electrospinning
and requires additional testing.
6.3.3 Targeted dendrimer vehicles as nanofiber patches: In chapter 2, we proposed the ability to
easily modify dendrimers with cell targeting ligands as a major advantage of the platform. In
chapter 4 we developed a dendrimer based nanofiber material that outperformed traditional eye
77

drops in terms of ease of application. In chapter 5 we synthesized a novel dendrimer nanoparticle
conjugate with potent IOP lowering bioactivity. The natural extension of this work is to combine
these ideas together into a single material. Electrospinning of G3-PEG-OTM is the most immediate
improvement that can be made. At least some of the variability observed in the animal IOP
response to these particles can be accounted for by the loss of drug during eye drop delivery. More
importantly, the long term storage stability of the dendrimer-prodrug linkage is not yet understood,
but there is reason to think it will not be robust (in the lab, these particles are stored as lyophilized
powder at 4°C and only hydrated immediately before use). Initial tests at electrospinning these
conjugates have not yet been successful. Electrospun fiber formation requires chain entanglements,
but dense cationic particles such as this favor disassociation in solution. Additional additives or
modifications will be needed to pull stable fibers.
Two approaches can be taken to improve the spin ability of this compound, changes to the
electrospinning parameters or changes to the vehicle. Modification of the electrospinning
parameters is likely the more desirable path as the work on bioactivity and safety will not have to
be re-done. At this time only attempts at varying electrospinning voltage, air gap distance, and
solution concentration have been tried. PEO concentration should be systematically investigated
next, as higher PEO concentrations may produce sufficient chain entanglements to form fibers, but
also because a more thorough understanding of PEO’s impact as a carrier polymer would benefit
the fundamental study of electrospinning overall. Humidity is another critical parameter neglected
in these studies that is known to have a major influence on fiber formation and efficiency.122
Unfortunately, our current electrospinning machine does not have humidity control, but it would
be a useful addition in future upgrades. If changes to the nanoparticle structure are made, reducing
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particle density and charge will increase the rate of chain entanglements, and therefore
electrospinning efficiency.
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